Cargando…

Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients

BACKGROUND: Many factors influence whether the first-line oral anti-diabetic drug, metformin, should be initiated to a patient with type 2 diabetes mellitus (T2DM) early in the course of management in addition to lifestyle modifications. This study aims to evaluate the net effects of metformin monot...

Descripción completa

Detalles Bibliográficos
Autores principales: Fung, Colman Siu Cheung, Wan, Eric Yuk Fai, Wong, Carlos King Ho, Jiao, Fangfang, Chan, Anca Ka Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600251/
https://www.ncbi.nlm.nih.gov/pubmed/26453464
http://dx.doi.org/10.1186/s12933-015-0304-2
_version_ 1782394394088833024
author Fung, Colman Siu Cheung
Wan, Eric Yuk Fai
Wong, Carlos King Ho
Jiao, Fangfang
Chan, Anca Ka Chun
author_facet Fung, Colman Siu Cheung
Wan, Eric Yuk Fai
Wong, Carlos King Ho
Jiao, Fangfang
Chan, Anca Ka Chun
author_sort Fung, Colman Siu Cheung
collection PubMed
description BACKGROUND: Many factors influence whether the first-line oral anti-diabetic drug, metformin, should be initiated to a patient with type 2 diabetes mellitus (T2DM) early in the course of management in addition to lifestyle modifications. This study aims to evaluate the net effects of metformin monotherapy (MM) on the all-cause mortality and cardiovascular disease (CVD) events. METHODS: A retrospective 5-year follow-up cohort study was conducted on Chinese adult patients with T2DM and without any CVD history under public primary care. Cox proportional hazard regressions were performed to compare the risk of all-cause mortality and CVD events (CHD, stroke, heart failure) between patients receiving lifestyle modifications plus MM (MM groups) and those with lifestyle modifications alone (control groups). RESULTS: 3400 pairs of matched patients were compared. MM group had an incidence rate of 7.5 deaths and 11.3 CVD events per 1000 person-years during a median follow-up period of 62.5 months whereas control group had 11.1 deaths and 16.3 per 1000 person-years during a median follow-up period of 43.5–44.5 months. MM group showed a 29.5 and 30–35 % risk reduction of all-cause mortality and CVD events (except heart failure) than control group (P < 0.001). MM group was more prone to progress to chronic kidney disease but this was not statistically significant. CONCLUSIONS: Type 2 diabetic patients who were started on metformin monotherapy showed improvement in many of the clinical parameters and a reduction in all-cause mortality and CVD events than lifestyle modifications alone. If there is no contraindication and if tolerated, diabetic patients should be prescribed with metformin early in the course of the diabetic management to minimize their risk of having the cardiovascular events and mortality in the long run. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12933-015-0304-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4600251
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46002512015-10-11 Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients Fung, Colman Siu Cheung Wan, Eric Yuk Fai Wong, Carlos King Ho Jiao, Fangfang Chan, Anca Ka Chun Cardiovasc Diabetol Original Investigation BACKGROUND: Many factors influence whether the first-line oral anti-diabetic drug, metformin, should be initiated to a patient with type 2 diabetes mellitus (T2DM) early in the course of management in addition to lifestyle modifications. This study aims to evaluate the net effects of metformin monotherapy (MM) on the all-cause mortality and cardiovascular disease (CVD) events. METHODS: A retrospective 5-year follow-up cohort study was conducted on Chinese adult patients with T2DM and without any CVD history under public primary care. Cox proportional hazard regressions were performed to compare the risk of all-cause mortality and CVD events (CHD, stroke, heart failure) between patients receiving lifestyle modifications plus MM (MM groups) and those with lifestyle modifications alone (control groups). RESULTS: 3400 pairs of matched patients were compared. MM group had an incidence rate of 7.5 deaths and 11.3 CVD events per 1000 person-years during a median follow-up period of 62.5 months whereas control group had 11.1 deaths and 16.3 per 1000 person-years during a median follow-up period of 43.5–44.5 months. MM group showed a 29.5 and 30–35 % risk reduction of all-cause mortality and CVD events (except heart failure) than control group (P < 0.001). MM group was more prone to progress to chronic kidney disease but this was not statistically significant. CONCLUSIONS: Type 2 diabetic patients who were started on metformin monotherapy showed improvement in many of the clinical parameters and a reduction in all-cause mortality and CVD events than lifestyle modifications alone. If there is no contraindication and if tolerated, diabetic patients should be prescribed with metformin early in the course of the diabetic management to minimize their risk of having the cardiovascular events and mortality in the long run. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12933-015-0304-2) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-09 /pmc/articles/PMC4600251/ /pubmed/26453464 http://dx.doi.org/10.1186/s12933-015-0304-2 Text en © Fung et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Investigation
Fung, Colman Siu Cheung
Wan, Eric Yuk Fai
Wong, Carlos King Ho
Jiao, Fangfang
Chan, Anca Ka Chun
Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients
title Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients
title_full Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients
title_fullStr Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients
title_full_unstemmed Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients
title_short Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients
title_sort effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on chinese type 2 diabetes mellitus patients
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600251/
https://www.ncbi.nlm.nih.gov/pubmed/26453464
http://dx.doi.org/10.1186/s12933-015-0304-2
work_keys_str_mv AT fungcolmansiucheung effectofmetforminmonotherapyoncardiovasculardiseasesandmortalityaretrospectivecohortstudyonchinesetype2diabetesmellituspatients
AT wanericyukfai effectofmetforminmonotherapyoncardiovasculardiseasesandmortalityaretrospectivecohortstudyonchinesetype2diabetesmellituspatients
AT wongcarloskingho effectofmetforminmonotherapyoncardiovasculardiseasesandmortalityaretrospectivecohortstudyonchinesetype2diabetesmellituspatients
AT jiaofangfang effectofmetforminmonotherapyoncardiovasculardiseasesandmortalityaretrospectivecohortstudyonchinesetype2diabetesmellituspatients
AT chanancakachun effectofmetforminmonotherapyoncardiovasculardiseasesandmortalityaretrospectivecohortstudyonchinesetype2diabetesmellituspatients